Asimadoline and its potential for the treatment of diarrhea-predominant irritable bowel syndrome: A review

Clinical and Experimental Gastroenterology

Volumn 5, Issue 1, 2012, Pages 1-10

  Mangel, Allen W ^a   Hicks, Gareth A ^b  

^a RTI HEALTH SOLUTIONS   (United States)

^b Tioga Pharmaceuticals Inc   (United States)

Author keywords

Asimadoline; Irritable bowel syndrome; Kappa opioid agonist; Visceral hypersensitivity; Visceral pain

Indexed keywords

ASIMADOLINE; CALCITONIN GENE RELATED PEPTIDE; KAPPA OPIATE RECEPTOR; KAPPA OPIATE RECEPTOR AGONIST; KETOCONAZOLE; MU OPIATE RECEPTOR AGONIST; PLACEBO; SUBSTANCE P; VASOPRESSIN;

ABDOMINAL PAIN; ANALGESIC ACTIVITY; ANTIDIARRHEAL ACTIVITY; AREA UNDER THE CURVE; BLOOD BRAIN BARRIER; CONSTIPATION; DIARRHEA; DIURESIS; DIZZINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG PENETRATION; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG SELECTIVITY; DYSPHORIA; EUPHORIA; FATIGUE; HUMAN; IRRITABLE COLON; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NONHUMAN; PAIN THRESHOLD; PHARMACODYNAMICS; PHARMACOLOGY; POLYURIA; RESPIRATION DEPRESSION; REVIEW; SEDATION; SIDE EFFECT; SINUSITIS; SPINAL GANGLION; THIRST; TIME TO MAXIMUM PLASMA CONCENTRATION; VISCERAL PAIN; VISUAL ANALOG SCALE; VOMITING; XEROSTOMIA;

EID: 84856789344     PISSN: None     EISSN: 11787023     Source Type: Journal    
DOI: 10.2147/ceg.s23274     Document Type: Review

References (71)

1. Everhart JE, Renault PF. Irritable bowel syndrome in office-based practices in the United States. Gastroenterology. 1991;100(4):998-1005.
2. Russo MW, Gaynes BN, Drossman DA. A national survey of practice patterns of gastroenterologists with comparison to the past two decades. J Clin Gastroenterol. 1992;29(4):339-343.
3. Mayer EA. Clinical practice. Irritable bowel syndrome. N Engl J Med. 2008;358(16):1692-1699.
4. Watson ME, Lacey L, Kong S, et al. Alosetron improves quality of life in women with diarrhea-predominant irritable bowel syndrome. Am J Gastroenterol. 2001;96(2):455-459.
5. Wells NE, Hahn BA, Whorwell PJ. Clinical economics review: irritable bowel syndrome. Aliment Pharmacol Ther. 1997;11(6):1019-1030.
6. Whitehead WE, Burnett CK, Cook EW III, Taub E. Impact of irritable bowel syndrome on quality of life. Dig Dis Sci. 1996;41(11): 2248-2253.
7. Corney RH, Stanton R. Physical symptom severity, psychological and social dysfunction in a series of outpatients with irritable bowel syndrome. J Psychosom Res. 1990;34(5):483-491.
8. Hahn BA, Yan S, Strassels S. Impact of irritable bowel syndrome on quality of life and resource use in the United States and United Kingdom. Digestion. 1999;60(1):77-81.
9. Andrews EB, Eaton SC, Hollis KA, et al. Prevalence and demographics of irritable bowel syndrome: results from a large web-based survey. Aliment Pharmacol Ther. 2005;22(10):935-942.
10. Patel RP, Petitta A, Fogel A, Peterson E, Zarowitz BJ. The economic impact of irritable bowel syndrome in a managed care setting. J Clin Gastroenterol. 2002;35(1):14-20.
11. Levy RL, Von Korff M, Whitehead WE, et al. Costs of care for irritable bowel syndrome in a health maintenance organization. Am J Gastroenterol. 2001;96(11):3122-3129.
12. Sandler RS. Epidemiology of irritable bowel syndrome in the United States. Gastroenterology. 1990;99(2):409-415.
13. Drossman DA, Li Z, Andruzzi E, et al. U.S. householder survey of functional gastrointestinal disorders. Prevalence, sociodemography, and health impact. Dig Dis Sci. 1993;38(9):1569-1580.
14. Hungin AP, Whorwell PJ, Tack J, Mearin F. The prevalence patterns and impact of irritable bowel syndrome: an international survey of 40,000 subjects. Aliment Pharmacol Ther. 2003;17(5):643-650.
15. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. In: Drossman DA, Corazziari E, Delvaux M, et al, editors. Rome III: The Functional Gastrointestinal Disorders. McLean, VA: Degnon Associates Inc; 2006.
16. Mangel AW, Northcutt AR. Review article: the safety and efficacy of alosetron, a 5-HT3 receptor antagonist, in female irritable bowel syndrome patients. Aliment Pharmacol Ther. 1999;13(Suppl 2): 77-82.
17. Camilleri M, Chey WY, Mayer EA, et al. A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome. Arch Int Med. 2001;161(14):1733-1740.
18. Pimentel M, Lembo A, Chey WD, et al; for TARGET Study Group. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Eng J Med. 2011;364(1):22-32.
19. Pimentel M, Lembo A, Chey WD, et al; for TARGET Study Group. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Eng J Med. 2011;364(1): Supplementary Appendix.
20. Tack J, Müller-Lissner S, Bytzer P, et al. A randomised controlled trial assessing the efficacy and safety of repeated tegaserod therapy in women with irritable bowel syndrome with constipation. Gut. 2005;54(12): 1707-1713.
21. Müller-Lissner SA, Fumagalli I, Bardhan KD, et al. Tegaserod, a 5-HT(4) receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation. Aliment Pharmacol Ther. 2001;15(10):1655-1666.
22. Drossman DA, Chey WD, Johanson JF, et al. Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome - results of two randomized, placebo-controlled studies. Aliment Pharmacol Ther. 2009;29(3):329-341.
23. Johnston JM, Kurtz CB, Macdougall JE, et al. Linaclotide improves abdominal pain and bowel habits in a phase IIb study of patients with irritable bowel syndrome with constipation. Gastroenterology. 2010;139(6):1877-1886.
24. American College of Gastroenterology Task Force on Irritable Bowel Syndrome, Brandt LJ, Chey WD, Foxx-Orenstein AE, et al. An evidence- based position statement on the management of irritable bowel syndrome. Am J Gastroenterol. 2009;104 (Suppl 1):S1-S35.
25. Walsh SL, Strain EC, Abreu ME, Bigelow GE. Enadoline, a selective kappa opioid agonist: comparison with butorphanol and hydromorphone in humans. Psychopharmacology (Berl). 2001;157(2):151-162.
26. Barber A, Bartoszyk GD, Bender HM, et al. A pharmacological profile of the novel, peripherally-selective kappa-opioid receptor agonist, EMD 61753. Br J Pharmacol. 1994;113(4):1317-1327.
27. Su X, Joshi SK, Kardos S, Gebhart GF. Sodium channel blocking actions of the kappa-opioid receptor agonist U50,488 contribute to its visceral antinociceptive effects. J Neurophysiol. 2002;87(3):1271-1279.
28. Joshi SK, Lamb K, Bielefeldt K, Gebhart GF. Arylacetamide kappaopioid receptor agonists produce a tonic- and use-dependent block of tetrodotoxin-sensitive and -resistant sodium currents in colon sensory neurons. J Pharmacol Exp Ther. 2003;307(1):367-372.
29. Jonker JW, Wagenaar E, van Deemter L, et al. Role of blood-brain barrier P-glycoprotein in limiting brain accumulation and sedative side-effects of asimadoline, a peripherally acting analgesic drug. Br J Pharmacol. 1999;127(1):43-50.
30. Barber A, Gottschlich R. Novel developments with selective, nonpeptidic kappa-opioid receptor agonists. Expert Opin Investig Drugs. 1997;6(10):1351-1368.
31. Bender HM, Dasenbrock J. Brain concentrations of asimadoline in mice: the influence of coadministration of various P-glycoprotein substrates. Int J Clin Pharmacol Ther. 1998;36(2):76-79.
32. Slizgi GR, Ludens JH. Studies on the nature and mechanism of the diuretic activity of the opioid analgesic ethylketocyclazocine. J Pharmacol Exp Ther. 1982;220(3):585-591.
33. Rimoy GH, Bhaskar NK, Wright DM, Rubin PC. Mechanism of diuretic action of spiradoline (U-62066E) - a kappa-opioid receptor agonist in the human. Br J Clin Pharmacol. 1991;32(5):611-615.
34. Brooks DP, Giardina G, Gellai M, et al. Opiate receptors within the blood-brain barrier mediate kappa agonist-induced water diuresis. J Pharmacol Exp Ther. 1993;266(1):164-171.
35. Ashton N, Balment RJ, Blackburn TP. Kappa-opioid-receptor agonists modulate the renal excretion of water and electrolytes in anaesthetized rats. Br J Pharmacol. 1990;99(1):181-185.
36. Kramer HJ, Uhl W, Ladstetter B, Bäcker A. Influence of asimadoline, a new kappa-opioid receptor agonist, on tubular water absorption and vasopressin secretion in man. Br J Clin Pharmacol. 2000;50(3): 227-235.
37. Jordan B, Devi LA. Molecular mechanisms of opioid receptor signal transduction. Br J Anaesth. 1998;81(1):12-19.
38. North RA. Opioid receptor types and membrane ion channels. Trends Neurosci. 1986;9:114-117.
39. Herz A. Peripheral opioid analgesia - facts and mechanisms. Prog Brain Res. 1996;110:95-104.
40. Diop L, Rivière PJ, Pascaud X, Junien JL. Peripheral kappa-opioid receptors mediate the antinociceptive effect of fedotozine (correction of fetodozine) on the duodenal pain reflex in rat. Eur J Pharmacol. 1994;271(1):65-71.
41. Harada Y, Nishioka K, Kitahata LM, Nakatani K, Collins JG. Contrasting actions of intrathecal U50, 488H, morphine, or [D-Pen2, D-Pen5] enkephalin or intravenous U50, 488H on the visceromotor response to colorectal distension in the rat. Anesthesiology. 1995;83(2): 336-343.
42. Danzebrink RM, Green SA, Gebhart GF. Spinal mu and delta, but not kappa, opioid-receptor agonists attenuate responses to noxious colorectal distension in the rat. Pain. 1995;63(1):39-47.
43. Sengupta JN, Su X, Gebhart GF. Kappa, but not mu or delta, opioids attenuate responses to distention of afferent fibers innervating the rat colon. Gastroenterology. 1996;111(4):968-980.
44. Su X, Sengupta JN, Gebhart GF. Effects of kappa-opioid receptorselective agonists on responses of pelvic nerve afferents to noxious colorectal distension. J Neurophysiol. 1997;78(2):1003-1012.
45. Delvaux M, Beck A, Jacob J, et al. Effect of asimadoline, a kappa opioid agonist, on pain induced by colonic distension in patients with irritable bowel syndrome. Aliment Pharmacol Ther. 2004;20(2):237-246.
46. Rivière PJ. Peripheral kappa-opioid agonists for visceral pain. Br J Pharmacol. 2004;141(8):1331-1334.
47. Sengupta JN, Snider A, Su X, Gebhart GF. Effects of kappa opioids in the inflamed rat colon. Pain. 1999;79(2-3):175-185.
48. Burton MB, Gebhart GF. Effects of kappa-opioid receptor agonists on responses to colorectal distension in rats with and without acute colonic inflammation. J Pharmacol Exp Ther. 1998;285(2): 707-715.
49. Walker JS, Scott C, Bush KA, Kirkham BW. Effects of the peripherally selective kappa-opioid asimadoline, on substance P and CGRP mRNA expression in chronic arthritis of the rat. Neuropeptides. 2000;34(3-4):193-202.
50. Binder W, Scott C, Walker JS. Involvement of substance P in the anti-inflammatory effects of the peripherally selective kappa-opioid asimadoline and the NK1 antagonist GR205171. Eur J Neurosci. 1999;11(6):2065-2072.
51. Berg KA, Rowan MP, Sanchez TA, et al. Regulation of κ-opioid receptor signaling in peripheral sensory neurons in vitro and in vivo. J Pharmacol Exp Ther. 2011;338(1):92-99.
52. Bi J, Tsai NP, Lin YP, Loh HH, Wei LN. Axonal mRNA transport and localized translational regulation of kappa-opioid receptor in primary neurons of dorsal root ganglia. Proc Natl Acad Sci U S A. 2006;103(52): 19919-19924.
53. Bi J, Tsai NP, Lu HY, Loh HH, Wei LN. Copb1-facilitated axonal transport and translation of kappa opioid-receptor mRNA. Proc Natl Acad Sci U S A. 2007;104(34):13810-13815.
54. Tsai NP, Bi J, Loh HH, Wei LN. Netrin-1 signaling regulates de novo protein synthesis of kappa opioid receptor by facilitating polysomal partition of its mRNA. J Neurosci. 2006;26(38):9743-9749.
55. Tsai NP, Bi J, Wei LN. The adaptor Grb7 links netrin-1 signaling to regulation of mRNA translation. EMBO J. 2007;26(6):1522-1531.
56. Delgado-Aros S, Chial HJ, Camilleri M, et al. Effects of a kappa-opioid agonist, asimadoline, on satiation and GI motor and sensory functions in humans. Am J Physiol Gastrointest Liver Physiol. 2003;284(4): G558-G566.
57. Mangel AW, Bornstein JD, Hamm LR, et al. Clinical trial: asimadoline in the treatment of patients with irritable bowel syndrome. Aliment Pharmacol Ther. 2008;28(2):239-249.
58. Chamouard P, Klein A, Martin E, Adloff M, Angel F. Regulatory role of enteric kappa opioid receptors in human colonic motility. Life Sci. 1993;53(14):1149-1156.
59. Giuliani S, Lecci A, Tramontana M, Maggi CA. Role of kappa opioid receptors in modulating cholinergic twitches in the circular muscle of guinea-pig colon. Br J Pharmacol. 1996;119(5):985-989.
60. Poonyachoti S, Kulkarni-Narla A, Brown DR. Chemical coding of neurons expressing delta- and kappa-opioid receptor and type I vanilloid receptor immunoreactivities in the porcine ileum Cell Tissue Res. 2002;307(1):23-33.
61. Bagnol D, Mansour A, Akil H, Watson SJ. Cellular localization and distribution of the cloned mu and kappa opioid receptors in rat gastrointestinal tract. Neuroscience. 1997;81(2):579-591.
62. Sternini C, Patierno S, Selmer IS, Kirchgessner A. The opioid system in the gastrointestinal tract. Neurogastroenterol Motil. 2004; 16(Suppl 2):3-16.
63. Pol O, Palacio JR, Puig MM. The expression of delta- and kappaopioid receptor is enhanced during intestinal inflammation in mice. J Pharmacol Exp Ther. 2003;306(2):455-462.
64. Kellow JE, Phillips SF. Altered small bowel motility in irritable bowel syndrome is correlated with symptoms. Gastroenterology. 1987;92(6):1885-1893.
65. Marciani L, Cox EF, Hoad CL, et al. Postprandial changes in small bowel water content in healthy subjects and patients with irritable bowel syndrome. Gastroenterology. 2010;138(2):469-477.
66. Deiteren A, Camilleri M, Burton D, McKinzie S, Rao A, Zinsmeister AR. Effect of meal ingestion on ileocolonic and colonic transit in health and irritable bowel syndrome. Dig Dis Sci. 2010;55(2):384-391.
67. Chey WY, Jin HO, Lee MH, Sun SW, Lee KY. Colonic motility abnormality in patients with irritable bowel syndrome exhibiting abdominal pain and diarrhea. Am J Gastroenterol. 2001;96(5): 1499-1506.
68. Bouchoucha M, Devroede G, Raynaud JJ, Bon C, Bejou B, Benamouzig R. Is the colonic response to food different in IBS in contrast to simple constipation or diarrhea without abdominal pain? Dig Dis Sci. 2011;56(10):2947-2956.
69. Mangel AW, Williams VS. Asimadoline in the treatment of irritable bowel syndrome. Expert Opin Investig Drugs. 2010;19(10):1257-1264.
70. Szarka L, Camilleri M, Burton D, et al. Efficacy of on-demand asimadoline, a peripheral k-opioid agonist, in females with irritable bowel syndrome. Clin Gastroenterol Hepatol. 2007;5(11):1268-1275.
71. Camilleri M. Novel pharmacology: asimadoline, a kappa-opioid agonist, and visceral sensation. Neurogastroenterol Motil. 2008;20(9): 971-979.